JSC Grindeks receives a certificate of Saudi Food and Drug Authority – Yahoo Finance

JSC Grindeks informs that the company has received a certification of Saudi Food and Drug Authority certifying the compliance of Grindeks final dosage forms tablets and capsules with the Saudi Arabias medicines manufacturing requirements.

The supervising institution of medicinal products in Saudi Arabia issued the certificate after a successful multi-step inspection of JSC Grindeks final dosage forms manufacturing site at Krustpils Street 53, Riga.

JSC Grindeks Chairman of the Board Juris Bundulis: The positive assessment of the compliance of Grindeks final dosage forms manufacturing site with the Saudi Arabias pharmaceutical manufacturing standard opens us new export opportunities to the Middle East region. The Saudi Food and Drug Authority is very demanding and rigorous, which is why its certification is highly valued in other Gulf countries."

In recent years, JSC Grindeks has been strategically expanding the range of oncological medicines therefore medicines of this therapeutic group will be the first with which JSC Grindeks plans to enter the Saudi Arabias market.

At the same time, the Saudi Food and Drug Authority is organizing an inspection at HBM Pharma in Slovakia, a subsidiary of JSC Grindeks, to evaluate the compliance of injections solutions with Saudi Arabias medicines manufacturing requirements.

About JSC Grindeks

Grindeks is an international pharmaceutical company focused on research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients. The Group of Grindeks has four subsidiary companies in Latvia, Estonia, and Slovakia as well as representative offices in 11 countries.

Grindeks specializes in the heart and cardiovascular, CNS, anti-cancer and gastroenterological medication therapeutic groups. A range of products covers a combination of original products Mildronate (meldonium*) and Ftorafur, generics, food supplements and active pharmaceutical ingredients.

In 2018, products of the company were exported to 87 countries with export comprising 93% of the total turnover. The most significant Grindeks markets include the EU countries, Russia and the other CIS countries, the U.S., Canada, Japan and Vietnam.

Story continues

To increase production capacity and develop infrastructure, the company has accomplished many significant investment projects, investing nearly 105 million euros over the last 15 years.

*Notice: meldonium is included in the list of substances prohibited in sport.

Further information:

Laila KlavinaHead of the Communications Department, JSC GrindeksPhones: (+371) 67083370, (+371) 29256012Fax: (+371) 67083505laila.klavina@grindeks.lvwww.grindeks.eu

Visit link:

JSC Grindeks receives a certificate of Saudi Food and Drug Authority - Yahoo Finance